Burning around $4m a quarter, should get us to mid next year for a capital raise at a higher price. But only 2 trials disclosed, hopefully we have a new trial initiated ever quarter til H2 2025.
1. Phase 2 blood cancer trial
2. CMML German trial
3. iRBD Parkinson’s (more to come)
No mention of Scar treatment though, let’s hope we get an update on this in the next 2 months.
On track, but not bolting out the gates, so probably why we’re still so cheap.
Add to My Watchlist
What is My Watchlist?
